Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Zymeworks

Zymeworks (NASDAQ: ZYME) insider transactions

In the twelve months to 10 November 2026, executives and directors of Zymeworks reported 11 open-market sales of 201,765 shares ($5.0m) and 0 open-market purchases, by 5 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Zymeworks shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
9 October 2026Schayowitz AdamEVP, Head of R&DOption exercise+37,037—37,037Form 4
9 October 2026Schayowitz AdamEVP, Head of R&DOpen-market sale−13,832$25.8523,205Form 4
6 July 2026Hollywood MarkEVP & Chief Operating OfficerGrant or award+939$22.22133,852Form 4
12 January 2026Hollywood MarkEVP & Chief Operating OfficerOption exercise+17,666—139,033Form 4
12 January 2026Hollywood MarkEVP & Chief Operating OfficerOpen-market sale−6,120$22.67132,913Form 4
12 January 2026Galbraith KennethChair & CEOOption exercise+64,000—257,266Form 4
12 January 2026Galbraith KennethChair & CEOOpen-market sale−30,424$22.67226,842Form 4
12 January 2026Moore Paul AndrewChief Scientific OfficerOption exercise+17,666—58,057Form 4
12 January 2026Moore Paul AndrewChief Scientific OfficerOpen-market sale−9,560$22.6748,497Form 4
12 January 2026Smith Jeffrey T LEVP & Chief Medical OfficerOption exercise+17,666—36,018Form 4
12 January 2026Smith Jeffrey T LEVP & Chief Medical OfficerOpen-market sale−9,310$22.6726,708Form 4
6 January 2026Patterson Leone DEVP, Chief Bus & Fin OfficerGrant or award+459$10.55459Form 4
5 January 2026Moore Paul AndrewChief Scientific OfficerOption exercise+17,168—40,501Form 4
5 January 2026Moore Paul AndrewChief Scientific OfficerOpen-market sale−9,289$25.1031,212Form 4
5 January 2026Moore Paul AndrewChief Scientific OfficerOption exercise+20,000—51,212Form 4
5 January 2026Moore Paul AndrewChief Scientific OfficerOpen-market sale−10,821$25.1040,391Form 4
5 January 2026Galbraith KennethChair & CEOOption exercise+47,668—180,943Form 4
5 January 2026Galbraith KennethChair & CEOOpen-market sale−22,657$25.10158,286Form 4
5 January 2026Galbraith KennethChair & CEOOption exercise+66,666—224,952Form 4
5 January 2026Galbraith KennethChair & CEOOpen-market sale−31,686$25.10193,266Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Zymeworks page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.